Non ci sono recensioni
Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.
It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.
The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.
The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.
This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
Front Matter
Pages i-xvi
PDF
Advances in Thyroid Cancer Management Beyond the Pandemic
Ujjal K. Mallick, Clive Harmer
Pages 1-8
Multidisciplinary Approach to Management of Thyroid Cancer
Front Matter
Pages 9-9
PDF
Review of NICE Thyroid Cancer Guidelines—UK 2022
Nick Reed
Pages 11-18
African Head and Neck Society Clinical Practice Guidelines for Thyroid Nodules and Cancer in Developing Countries and Limited Resource Settings
Johannes J. Fagan, Mark Zafereo, Kathryn Marcus, Marika D. Russell, Gregory Randolph
Pages 19-27
The Diagnosis of Thyroid Cancer
Front Matter
Pages 29-29
PDF
Ultrasonography in Diagnosis and Management of Thyroid Cancer: Current International Recommendations
Dong Gyu Na, Ji-hoon Kim, Eun Ju Ha
Pages 31-58
The Molecular Pathology of Thyroid Cancer
Mufaddal T. Moonim
Pages 59-73
Initial Thyroid Surgery
Front Matter
Pages 75-75
PDF
Management of Papillary Thyroid Microcarcinoma: A Japanese Experience
Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima
Pages 77-86
Advances in Thyroid Surgery
Erin Buczek, Teresa Kroeker, Cristian Slough, Damilola R. Fakunle, Amr H. Abdelhamid Ahmed, Gregory W. Randolph
Pages 87-99
Remote Access and Robotic Thyroidectomy: Current Status
Klaas Van Den Heede, Matilda Annebäck, Neil Tolley
Pages 101-110
Contentious Issues in the Management of the Neck in Well-Differentiated Thyroid Cancers
Ashok R. Shaha, R. Michael Tuttle
Pages 111-119
Post Surgical Management of Differentiated Thyroid Cancer
Front Matter
Pages 121-121
PDF
Radioiodine Dosimetric Approaches: Current Concepts and Future Directions
Jan Taprogge, Glenn Flux, Kate Garcez, Matthew Beasley, Jonathan Wadsley
Pages 123-132
External Beam Radiation in Differentiated Thyroid Cancer in the Era of IMRT and Modern Radiation Planning Techniques
Jelena Lukovic, James D. Brierley, Aruz Mesci
Pages 133-142
Management of Post-operative Hypocalcemia
Claudio Marcocci
Pages 143-159
On ART, and ART (Ablative Radioiodine Therapy)!
Furio Pacini, Ujjal K. Mallick
Pages 161-162
Follow Up and Longterm Management of Differentiated Thyroid Cancer
Front Matter
Pages 163-163
PDF
Radioiodine Refractory Thyroid Cancer
Fabian Pitoia, Anabella Smulever, Fernando Jerkovich
Pages 165-188
Medullary Thyroid Carcinoma and Familial Non Medullary Thyroid Cancer
Front Matter
Pages 189-189
PDF
Surgery for Medullary Thyroid Cancer
E. Gréant, A. R. Shaha, I. J. Nixon
Pages 191-200
Medullary Thyroid Cancer: Diagnosis and Non-surgical Management
Leslie Cheng, Kate Newbold
Pages 201-214
Familial Non-medullary Thyroid Cancer
Joanna Klubo-Gwiezdzinska, Yevgenia Kushchayeva, Sudheer Kumar Gara, Electron Kebebew
Pages 215-246
Thyroid Cancer in Children
Front Matter
Pages 247-247
PDF
Childhood Papillary Thyroid Carcinoma
Ian D. Hay
Pages 249-277
Aggressive Thyroid Cancers
Front Matter
Pages 279-279
PDF
Anaplastic Thyroid Cancer
Leslie Cheng, Kate Newbold
Pages 281-289
Primary Mesenchymal Tumors of the Thyroid
Jiangnan Hu, Rodas Kassu, Electron Kebebew
Pages 291-304
Future Developments and Directions for Research in Thyroid Cancer
Front Matter
Pages 305-305
PDF
Current Trends in Treatment and New Generation of Trials in Thyroid Cancer
Priyanka C. Iyer, Samer A. Srour, Marie Claude Hofmann, Maria E. Cabanillas
Pages 307-324
Thyroid Cancer Clinical Trials
Allan Hackshaw
Pages 325-341
Thyroid Cancer Survivorship: Contemporary Themes
Katherine Kendell, Nicola Jane Armstrong
Pages 343-368
Differentiated Thyroid Cancer: A Health Economic Review
Matilda Annebäck, Klaas Van Den Heede, Neil Tolley
Pages 369-377
Covid-Sars-2 Pandemic: The Impact on Management of Thyroid Cancer—Key Lessons Learnt for the Future
Front Matter
Pages 379-379
PDF
Thyroid Cancer Surgery During the Pandemic—UK Perspective
Sumrit Bola, Vinidh Paleri
Pages 381-386
Impact on Non Surgical Management and Trials of Thyroid Cancer
Kathleen A. Farnell, Jon Wadsley
Pages 387-390
Back Matter
Pages 391-399
Sei sicuro di voler eseguire questa azione?